BioCryst Partners With Shionogi On Influenza Antiviral In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Shionogi gains development and commercialization rights for peramivir in Japan in deal worth up to $130 million plus royalties for BioCryst.